Teva Pharm Stock Price, News & Analysis

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) has scheduled its third quarter 2025 financial results announcement for November 5, 2025. The company will release its financial results at 7:00 a.m. ET, followed by a conference call and live webcast at 8:00 a.m. ET.

Participants must register in advance to receive local or toll-free phone numbers and personal pins. The webcast will be accessible through Teva's investor relations website, with a replay available within 24 hours after the call.

Teva Pharmaceuticals (NYSE: TEVA) presented positive real-world survey data for AUSTEDO XR® (deutetrabenazine) at the 2025 Psych Congress Annual Meeting. The survey of 209 tardive dyskinesia (TD) patients showed remarkable treatment satisfaction, with over 94% reporting movement improvement and more than 89% expressing high satisfaction with the treatment.

Key findings revealed that 77% of patients reported improved social comfort and emotional well-being, while 96% found the medication easy to take. The study included both patients with prior valbenazine use and those without prior treatment, with 96% of participants expressing interest in continuing AUSTEDO XR treatment.

Teva Pharmaceuticals (NYSE:TEVA) announced promising long-term safety data from its Phase 3 SOLARIS trial for olanzapine LAI (TEV-'749), a potential first-in-class long-acting injectable olanzapine treatment for schizophrenia. The trial demonstrated no post-injection delirium/sedation syndrome (PDSS) events through Week 56, with 3,470 total injections administered.

Key findings include a consistent safety profile with other olanzapine formulations, with 74% of participants reporting treatment-emergent adverse events. Common side effects included weight increase (36%) and injection site reactions. The study showed stable symptom improvement and maintained clinical effectiveness, with participants experiencing a mean weight increase of 5.6kg over 48 weeks.

Additionally, new data on UZEDY®, Teva's approved extended-release injectable risperidone, showed a 2.89-day shorter hospital stay compared to Invega Sustenna®, potentially saving $3,200 per hospitalization. Teva plans to submit an NDA for olanzapine LAI in H2 2025.

Teva Pharmaceutical (NYSE:TEVA) has announced plans to present data from its completed Phase 3 SOLARIS trial for Olanzapine LAI (TEV-'749) at the 2025 Psych Congress Annual Meeting in San Diego from September 17-21, 2025.

The company will host an analyst and investor conference call on September 22, 2025, at 11:00 a.m. ET to discuss the trial results. Participants must register in advance to obtain call-in details, and a live webcast will be available on Teva's Investor Relations website, with an archived version accessible within 24 hours after the discussion.

Teva Pharmaceuticals (NYSE: TEVA) announced that the FDA has granted Fast Track designation for emrusolmin (TEV-56286), their investigational treatment for Multiple System Atrophy (MSA). The drug, currently in Phase 2 development, targets the alpha synuclein protein involved in MSA pathogenesis.

Emrusolmin, developed in collaboration with MODAG GmbH, previously received Orphan Drug designation in 2022. The Fast Track status aims to expedite the development and review process for this potential treatment of MSA, a rare and progressive neurodegenerative disorder with no current cure or disease-modifying treatments.

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) has announced that its President and CEO, Richard Francis, will participate in two major healthcare investor conferences in September 2025. Francis will present at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9 at 8:30 A.M. ET and at the BofA Global Healthcare Conference 2025 in London on September 24 at 9:00 A.M. BST (4:00 A.M. ET).

Investors can access live webcasts of both presentations through Teva's Investor Relations website, with archived versions available within 24 hours after each live discussion.

Teva Pharmaceuticals (NYSE: TEVA) has received FDA approval and launched the first-ever generic version of Saxenda® (liraglutide injection), a GLP-1 receptor agonist for weight loss. This groundbreaking generic is indicated for adults with obesity or overweight with weight-related medical conditions, and pediatric patients aged 12-17 years weighing over 60 kg with obesity.

The approval marks Teva's fifth first-to-market generic entry this year, reinforcing their position as a Generics Powerhouse. The reference drug Saxenda® reported annual sales of $165 million as of June 2025, representing a significant market opportunity. The medication is designed to be used in combination with reduced calorie diet and increased physical activity for long-term weight management.

Teva Pharmaceuticals (NYSE: TEVA) has received FDA approval for an expanded indication of AJOVY® (fremanezumab-vfrm) for preventive treatment of episodic migraine in children and adolescents aged 6-17 years weighing 45kg or more. This milestone makes AJOVY the first and only CGRP antagonist approved for pediatric episodic migraine prevention.

The treatment, which can be administered monthly either in-office or at home, addresses a significant medical need, as 1 in 10 children and adolescents in the U.S. suffer from migraine. This expansion builds upon AJOVY's initial U.S. approval in 2018 for adult patients, demonstrating Teva's commitment to broadening access to neuroscience therapies across age groups.

Teva Pharmaceuticals (NYSE:TEVA) reported strong Q2 2025 results, marking its 10th consecutive quarter of year-over-year growth. The company achieved revenues of $4.2 billion and increased its 2025 outlook for key innovative products. Notable highlights include AUSTEDO revenues of $498 million (+19%), AJOVY reaching $155 million (+31%), and UZEDY at $54 million (+120%).

The company reported GAAP EPS of $0.24 and Non-GAAP EPS of $0.66, a 9% increase year-over-year. Free cash flow grew 47% to $476 million. Teva remains on track to achieve a 30% operating profit margin by 2027 through its transformation programs, targeting ~$700 million in net savings.